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Summary
Objective: To determine the predictive value of serum levels of TIMP-1 and hyaluronic acid in a 1 year prospective study in hip osteoarthritis
(OA).
Methods: Twenty-nine patients with OA of the hip were enrolled in a 1-year prospective study (median follow-up, 13 months). Biochemical
analysis was used to assess TIMP-1 and hyaluronic acid at entry and at the end of the study. Radiographic evaluation with an assisted
computed program was performed to calculate progression of joint space narrowing. Statistical tests served to determine correlations
between observed serum levels and radiograph joint space narrowing.
Results: Among the 29 patients, 10 showed joint space narrowing greater than 0.6 mm per year. The initial concentration of TIMP-1 as well
as delta value of variation in serum levels of TIMP-1 (difference between TIMP-1 concentration at entry and at the end) correlated with the
progression of joint space narrowing. A cut-off value of 600 ng/ml of TIMP-1 allowed the patients who progressed slowly from those who
progressed more rapidly. Hyaluronic acid serum level was not predictive of evolution.
Conclusion: TIMP-1 serum level may serve to predict the evolution of patients with hip OA. © 2001 OsteoArthritis Research Society
International
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Hip osteoarthritis (OA) is a common and debilitating
disease1 that requires total hip prosthesis in a majority of
patients. Disease progression can be easily assessed
using plain radiographs. Currently, for long-term follow-up
studies, conventional radiography appears to be the most
suitable modality to assess articular cartilage thickness of
the hips and knees2,3. Accurate assessment of disease
progression requires direct measurement of joint space
narrowing (JSN). It has been shown that progression over
a short period of time was more accurately assessed by
joint space width measurement than by scoring using
composite indexes such as Kellgren–Lawrence (K–L)
grading system4. New techniques have been designed to
quantitatively and reproducibly measure the knee and hip
joint space5–9. These techniques include special devices
for microfocal radiography10 and semiautomated digital-
ized image analysers in combination with rigorous
standardization of the radiographical procedure11. The
use of a computer image analysis system has been
shown to improve sensitivity and to reduce intraobserver
variability12,13.300In most studies on hip OA, mean radiological progres-
sion of JSN has been evaluated as between 0.25 mm
and 0.35 mm per year with very large interindividual
variations14–18. Some patients show rapid progression
while in others cartilage destruction progresses more
slowly16–18. Standard X-rays cannot predict the evolution of
JSN, but can only evaluate the JSN at a given time. Thus,
identification of a biological marker that would predict the
evolution of OA is of great interest19. Such a marker could
also serve to assess the effectiveness of treatments
designed to prevent cartilage matrix degradation.
Cartilage degradation in OA is thought to be the conse-
quence of an imbalance between matrix metalloproteinase
activity (collagenases (MMP-1 and 13), gelatinases
(MMP-2 and MMP-9) and stromelysin (MMP-3) and corre-
sponding inhibitors, the tissue inhibitor metalloproteinases
(TIMPS)20–23. Agrecanase does not belong to the metallo-
proteinase family and is not fully inhibited by TIMPs24.
Production and activity of MMPs, especially MMP-3,
are highly increased during the OA process21,22,25–27.
Among the three different forms of TIMPs, TIMP-1 exhibits
the highest affinity for MMP-1, MMP-13, MMP-3 and
MMP-927,28, while TIMP-2 forms a complex with type IV
collagenase29.
Local production of MMPs and TIMPs in the joint could
be reflected by their levels in synovial fluid (SF)24,25.
Subsequent passage of these molecules from the SF into
the circulation may influence their serum levels19. Thus,
serum levels of MMP-3 has been shown to be increased in
patients with OA compared with unaffected subjects30.
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present in cartilage matrix (bound to proteoglycans) and in
synovial fluid (SF) as high molecular complexes31. The
main source of HA in the synovial fluid is thought to be the
synovial membrane32. The concentration of HA in SF is
decreased in the OA joint while its serum level is increased
compared to normal controls33,34. A recent report focuses
on the predictive value of HA on JSN during the evolution of
knee OA35.
Only a few studies on biological markers have been
performed in patients with hip OA. The aim of this study
was to evaluate the predictive value of serum levels of
TIMP and hyaluronic acid in a 1-year prospective study in
patients with hip OA.Patients and methods
PATIENTS
Thirty patients with hip OA were enrolled in this 1-year
prospective study. All were referred to the Department of
Rheumatology with symptomatic hip OA K-L II tp III and
fulfilled the ACR criteria for hip OA3. Patients with bilateral
hip OA could be included only if they suffered from one
side. Using a 100 mm visual analog scale, patients were
considered symptomatic if the scale was >40 mm in the
involved hip and symptom free when <20 mm. Exclusion
criteria were: total loss of radiographic joint space, total hip
arthroplasty needed in the further months, recent (1 month)
intraarticular injection of corticosteroids and hip OA second-
ary to alternative arthropathies (i.e. infectious or inflamma-
tory arthritis, hip injury, aseptic osteonecrosis, congenital
abnormality such as congenital dislocation of the hip, K–L
of the contro-lateral hip>II). At entry a full clinical history
was taken and patients were examined to obtain the
following information: height, weight, pain on VAS, body
mass index (BMI), disease duration and date of diagnosis,
clinical presence of polyarticular OA involvement (Heber-
den or Bouchard’s nodes, clinical evidence of spine or knee
OA) and smoking status. Patients were on various drug
regimens including analgesics and numerous non-steroidal
antiinflammatory drugs. None presented other severe
disabling diseases that could interfere with the evaluation
of HA and TIMPs.RADIOLOGICAL DATA
At entry and end-point, patients underwent a radiograph
of the pelvis, performed by the same radiologist, using an
identical radiographical procedure. Antero-posterior radio-
graphs of the pelvis were performed in a standing position
with 20° of internal rotation of the lower limbs. The focus-
film distance was 100 cm and the beam was aligned to the
top of pubic symphysis. Radiographic evaluation was made
by a single experienced observer. The films were blinded
for patient identity and date. Morphological evaluation of
the hips was made to assess the patterns of femoral
head migration within the acetabulum. Only patients with
superior femoral head migration (superolateral, supero-
intermediate and superomedial) were selected because of
the difficulties of measuring inferior or medial JSN11. Prior
to joint space measurement, the different films of a patient
were placed side by side on a light box to determine the
zone to analyse in order to measure the same zone in
consecutive X-rays. Both mean width of the joint space
(mean JSW) and the interbone distance at the narrowestpoint (minimal JSW) of the targeted hip were determined
with a digitalized image analysis computer using a pre-
viously published method9,12. After ensuring that the
computer was correctly calibrated through repeated
measurements of a line segment of known length
[coefficient of variation (CV) 0.2%] the X-ray of the joint to
be analysed was placed on the view box and digitized at a
resolution of 600×1200 pixels/inch and 256 grey levels.
Subtraction and magnification were performed to obtain a
very clear outline of the joint space. The joint space
contours were delineated with the mouse on the superior
convex margin of the femoral head and the inferior margin
of the acetabulum. The joint space area and the mean JSW
were automatically calculated. The minimal JSW was
obtained by measuring the interbone distance at the
narrowest point of the joint. The radius of the femoral head
(RH) was automatically given by the computer from three
peripheral points drawn using the mouse. Because two
radiographs of the same subject had to be compared, it
was necessary to look for possible differences in magnifi-
cation of the hip and to make adequate corrections. This
was done by measuring the RH of each film and then by
calculating the ratio RH of the measured film/RH of the
reference film. The intraobserver CV for repeated measure-
ments of the same film was 1.2%12. Progression of JSN
was calculated in mm.BLOOD SAMPLING
Blood samples in OA patients were collected in the
morning when they had been awake and physically active
for about 3 h. Blood samples were obtained at entry
(designated as T0) and at the end of follow-up (designated
as T1). After collection, serum was immediately frozen at
−80°C. Normal serum values for each molecule were
obtained by blood sampling in large studies on normal
populations. None of the controls presented symptomatic
OA.Determination of TIMP-1 serum level
The assays for TIMP-1 were performed on the Bayer
Immuno 1® analyser and were designed to detect the
relevant analyte in patient samples by application of a
sandwich assay methodology. In the first step the serum
sample is dispensed into a cuvette. Reagent R1, which is
an antibody specific for the respective antigen conju-
gated to fluorescein, and reagent R2, which is an anti-
body specific for the respective antigen conjugated to
alkalinephosphatase enzyme, are added simultaneously to
the sample in the cuvette. The antibodies have been
generated inhouse, so that we have the hybridoma clones
in our hands. The concentrations of the first antibody
(FITC-conjugate) is 1 g/ml, and of the second antibody
(alkaline-phosphatase conjugate) is 8 g/ml. This mixture is
incubated at 37°C in the reaction tray cuvette on the
Immuno 1 analyser. Magnetic particles coated with antifluo-
rescein antibody are added to the contents of the cuvette,
and the whole mixture is again incubated. Within this time
the immune complex formed in the previous step attaches
to the solid phase through a fluorescein–antifluorescein
linkage. After the incubation time, the complex is pulled to
the side of the cuvette by means of an external magnetic
field. The cuvette is washed and all reagents and serum
components not bound to the solid phase are removed.
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nitrophenyl phosphate substrate (pNPP). Kinetically deter-
mined linear rates of color formation at 405 nm are directly
proportional to the amount of sandwich complexes present
in the cuvette, which in turn is a measure of the antigen
initially present in the unknown sample. Calibrators for the
method were prepared as liquids in a Tris-buffered BSA
solution. The cubic-fit-through-zero-algorithm was used to
generate standard curves.
The between-run precision of the assay ranges from
4.7% to 3.2% CV. There is no age dependency in adults but
significantly higher TIMP-1 values are found in children.
The normal serum values were given by blood sampling on
large studies on normal populations for each molecule.
Controls for TIMP-1 consisted of serum from 225 healthy
blood donors, 116 women and 109 men. It was prepared as
above and tested with the Bayer Immuno 1® assay in order
to establish the reference range. Mean age was 40.1, S.D.
11.9 years (median 41). The women were aged 20–63
years (mean 40.1, S.D. 12.2 years, median 41) and the men
21–68 years (mean 40.2, S.D. 11.6 years, median 40).Determination of hyaluronic acid serum level
The hyaluronic acid assay on the Bayer Immuno 1®
showed some modifications compared to the other assays.
The HA assay used specific HA binding protein isolated
from bovine cartilage instead of antibodies36. HA in the
sample is complexed by HA binding protein using
swandwich assay format. Capturing is achieved by fluro-
resceinated HA binding protein, which is immobilized with
the help of magnetic particles coated with antifluorescein
antibodies. Detection of the analyte used biotinylated HA
binding protein and an anti-biotin antibody labeled with
alkaline phosphatase. Calibrators for the method were
prepared as liquids in a Tris buffer solution. The cubic-fit-
through-zero-algorithm was used to generate standard
curves.
Controls for HA consisted of serum from 200 male and
182 female healthy donors with five groups of age ranging
from 20 to 69 years (40 patients by sex and by group,
except the 60–69-year-old female group, which included
only 22 donors).STATISTICAL ANALYSIS
A computer database containing all measured data was
created. These were analysed using the Statview S12 file.
Linear regression was used to investigate the correlations
between continuous variables. When the distribution ofvalues was not normal, log-transformed data were used for
statistical analysis.
Student’s two-tailed paired t-test and the non-parametric
Mann–Whitney U-test were performed on each set of
variables. Factors found to be associated in univariate
analysis were then studied in multivarate analysis.
P-values <0.05 were considered statistically significant. All
statistics were performed for mean JSW and minimal JSW,
but results were reported mainly for mean JSW because
they were highly correlated and mean JSW had the best
reproducibility10.ResultsEPIDEMIOLOGICAL DATA
One patient was excluded from analysis because of poor
quality of the hip radiograph at 12 months of follow-up.
Twenty-nine patients were analysed: 16 women, mean age
(±S.D.) 62 (±10) (range 40–81) and 13 men, mean age
55±13 (range 24–76). The mean follow-up was 13.7
months (10–14 months). The mean pain at VAS at entry
was 68 mm (range 42–48 mm). Hip OA was bilateral in 19
cases and isolated in 10. Typical radiographic findings of
OA were present in all patients (Kellgren–Lawrence grades
II and III). The localization of hip OA was superior and
external in 18 cases, superointernal in five cases and
superoaxial in six cases. The mean BMI was 25.7 (±4.62).
Ten patients were regular smokers (>200 cigarettes/year).
Fifteen subjects had generalized OA.Table I
Values of joint space width and of biological markers at entry and after 1 year of follow-up
T0 T1 T1–T0
(T0 vs T1)
Control
Mean JSW (mm) 2.25±1.19 1.88±1.12 0.57±0.55
Minimal JSW (mm) 1.76±1.13 1.24±1.08 0.52±0.494
TIMP (ng/ml) 529.7±197.9 493.5±190.2 36±102.58 617±107
HA (ng/ml) 54.7±38.3 51.7±38.8 3.07±38.7 34.7±22.4 (men)
34.06±18.9 (women)
T0: Value at the beginning of the study; T1: value at the end of the study (median of follow-up:13 months).
Mean JSW: mean joint space width. Minimal JSW: minimal joint space width (at the narrowest point). TIMP-1:
Tissue inhibitor of matrixmetalloproteinase-1. MMP 9/TIMP-1: Matrix metalloproteinase/TIMP-1. HA: Hyaluronic
acid. P: difference between T0 and T1 values, Mann–Whitney U-test.EVOLUTION OF SERUM LEVEL OF TIMP-1, HYALURONIC ACID
THROUGH THE OBSERVED PERIOD OF TIME
Results are summarized in Table I.
Serum level of TIMP-1 at the entry [529.7±197.9 (S.D.)
ng/ml] and at the end [493.5±190.2 (S.D.) ng/ml] were not
statistically different from in the control population
(617±107 ng/ml) (P=NS). TIMP-1 serum levels between
the beginning and the end of the study were not statistically
different. There was no difference in TIMP-1 serum level
according to sex (P=0.25), the uni- or bilateral form of hip
OA (P=0.94), smokers or non-smokers (P=0.54) and
patients with generalized OA (P=0.89). The  TIMP-1 was
not significant between patients with unilateral or bilateral
hip OA (P=0.82).
There was no difference in the serum level of hyaluronic
acid between the beginning and the end of the study
(Table I). Values in OA (54.7±38.3 ng/ml) were higher than
in controls where there is a strong age dependency.
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(mean±S.D.) to 34.7±22.47 ng/ml for male and from
8.16±8.2 ng/ml to 34.06±18.96 ng/ml for female subjects
from ages 20–69. In controls with the oldest age (60–69
years) values were 34.7±22.4 (S.D.) ng/ml for men and
(N=40) 34.06±18.9 (S.D.) ng/ml for women.
There was no difference in serum level of HA in bilateral
vs unilateral hip OA at entry: bilateral form: 63.6±43.2 ng/
ml vs unilateral: 38.4±22.1 ng/ml, P=0.11. This difference
reached a significant level at the end of the study: bilateral
form: 63.7±40.3 ng/ml vs unilateral: 23.9±18.8 ng/ml,
P=0.009.RADIOGRAPHIC EVOLUTION
Results are summarized in Table I.The symptomatic (targeted) hip
The mean joint space in the targeted hip was 2.25±1.19
(S.D.) mm at entry and 1.88±1.12 (S.D.) mm at the end of the
study. There was no difference in mean joint space in the
symptomatic hip joint between uni- and bilateral forms
(P=0.92). The mean annual progression of JSN was
0.43 mm/year (median 0.36 mm/year, range 0–2.2).
Evolution of minimal JSN was 0.037±0.032 mm/month.
On the basis of findings reported by Dougados et al.,
progression of JSN of 0.6 mm/year was chosen to differen-
tiate patients (N=10) with rapid evolution (progressors
>0.6 mm/year) from those (N=19) with slow evolution
(non-progressors<0.6 mm/year)15.The contralateral hip in case of bilateral
involvement
The narrowest point in the contralateral hip was at entry:
2.46±1.2 mm and at the end: 2.35±1.3 mm (not statisti-
cally significant, P=0.06). The mean progression in the
contralateral hip (asymptomatic) was 0.13±0.3 mm. The
rate of progression at the narrowest point in the targeted
hip (0.5±0.5 mm) was statistically superior than in the
contralateral hip (0.13±0.3 mm) P=0.03, meaning that the
symptomatic hip clearly progressed more rapidly. More-
over, there was no statistical correlation between the rate of
progression in the involved hip and the contralateral hip:
R= −0.10, P=0.63.
Thus the rate of evolution of the contralateral hip did not
influence the rate of progression in the targeted hip.CORRELATIONS BETWEEN THE SERUM LEVEL OF TIMP-1 AND
HYALURONIC ACID
There was no correlation between TIMP-1 and
hyaluronic acid levels at any period of the study.CORRELATIONS BETWEEN THE SERUM LEVEL OF TIMP-1,
HYALURONIC ACID AND RADIOLOGICAL PROGRESSION IN THE
TARGETED HIPTIMP-1 serum level and radiological progression
Correlations between serum levels and joint space are
shown in Fig. 1.Serum levels of TIMP-1 at entry and at the end of
follow-up (TIMP-T0, TIMP-T1) were not correlated with the
joint space thickness (neither for mean JSW nor for minimal
JSW). This suggests that TIMP-1 serum level does not
depend on the thickness of the articular cartilage.
Most interesting was the finding of correlations between
TIMP-1 serum level at entry and mean JSN (R=0.45,
P=0.02) (Figs 1 and 2). Since the distribution of JSN and
TIMP serum level was not normal, log transformed data
were used.
Non-progressors showed a significantly higher level of
TIMP-1 at entry (589 ng/ml±217.6) than progressors
(416 ng/ml±73.9). The difference was highly statistically
significant, P=0.01 (ANOVA test) (Fig. 3). The delta
(changes over time) of TIMP-1 in the progressors
was 25.7±9.29 ng/ml compared to 62.3±67.7 ng/ml in the
non-progressors, P>0.05, non-significant (ANOVA test).
A cut-off value of 600 ng/ml of TIMP-1 corresponding to
the value of the control population was chosen. This value
allows differentiation of patients with rapid evolution (TIMP-
1<600 ng/ml, JSN=0.53 mm/year±0.40) from patients
with slow evolution (TIMP-1>600 ng/ml, JSN=0.15 mm/
year±0.13) (P=0.02) (Fig. 4).
When looking at the minimal JSW, the same biological
meaning was found. Indeed, the JSN measured at the
narrowest point (minimal JSW) was correlated with the
TIMP-1 serum level at entry: R=0.38, P=0.03.Fig. 1. Correlation between TIMP-1 serum levels (ng/ml) and
radiographical JNS (log transformed data) in patients with hip OA.Influence of the evolution of the contralateral hip in
case of bilateral involvement and TIMP-1 serum
level
There was no correlation between the JSN in the
controlateral hip and the TIMP-1 serum level at entry:
R=0.15, P=0.48.
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progression
There was no correlation between any serum levels of
HA and progression of the disease in terms of JSN.Fig. 2. Correlation between variations of TIMP-1 serum levels (
TIMP-1 ng/ml) over 1 year follow-up and radiographical JNS (log
transformed data) in patients with hip OA.Fig. 3. TIMP-1 serum level at entry (ng/ml) of the study according
to the rate of progression of the radiographical JSN in patients with
hip OA (JSN mm/year; 10 patients with >0.6 mm/year and 19
patients with <0.6 mm/year).Fig. 4. Rate of progression of the radiological JSN (JSN mm/
month) according to TIMP-1 serum levels (ng/ml) (cut-off value of
600 ng/ml; 10 patients >600 ng/ml) at entry of the study in patients
with hip OA.Discussion
In this 1-year prospective study in patients with
symptomatic hip OA, we show that low serum TIMP-1 level
at entry may predict a rapid progression of JSN. We
selected only patients with one side symptomatic hip OA,
though some of them presented with a JSN of the contra-
lateral hip. As shown in this and in previously published
studies, there are large interindividual variations in disease
progression. JSN of 0.6 mm/year was chosen according to
Dougados et al. to define patients with rapid progression15.
In an attempt to predict radiological evolution, we looked at
markers that are involved in the disease process,
especially TIMP-1. A significant correlation between low
serum level of TIMP-1 at entry and progression of JSN
indicates that low serum level of TIMP-1 may predict
cartilage destruction. Our data suggest that a serum level
of TIMP-1 lower than 600 ng/ml is associated with a more
rapid JSN of more than 0.6 mm/year.
Numerous confounding factors should be take into
account before interpreting the predictive value of a serum
marker in OA. In our study, factors such as BMI, smoking,
generalized OA, localization of the hip OA and consumption
of NSAIDs or analgesics, did not influence the predictive
value of serum level of TIMP-1 at entry. Nineteen patients
presented with bilateral hip involvement which may
constitute a confounding factor in the interpretation of our
results. We showed that the evolution of the contralateral
hip was slow (0.13±0.3 mm/year) and was not correlated
with the evolution of the targeted hip. Moreover, there was
no correlation between the rate of progression in the
contralateral hip and the TIMP-1 serum level at entry.
Finally, the diffuse involvement of the osteoarthritic pro-
cess, which may affect sites that are not always evaluated,
such as the spine, represents another limiting factor.
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given time in OA of lower limbs is of poor value30; we did
not observe any correlations between TIMP-1 serum levels
and joint space thickness at given times (entry and end of
the study). There was no difference in the initial joint space
between patients over or under 600 ng/ml at entry into the
study. In other words, high TIMP-1 serum level was not
correlated with higher joint space thickness.
In our hands, serum levels of TIMP-1 in OA were higher
than that reported in the literature (192 ng/ml+40)30.
Though we have no clear explanation for those differences,
TIMP-1 serum level may be influenced by morning activity
and therefore by the time of the puncture30. Determination
of TIMP may include forms that are both unbound and
bound to MMPS30,37. We used a standardized method that
gives a higher level in normal controls, an average of
617 ng/ml. However, as previously reported, we did not find
any statistical difference in TIMP-1 serum level between
our OA group and controls30. However, the most appropri-
ate control group should be at best represented by patients
with unilateral asymptomatic hip OA.
Therefore it is tempting to postulate (though it is only
speculative) that a decreased serum level of TIMP-1 is the
consequence of a decrease in local production (and/or
increased comsumption) of TIMP-1, which contributes to
cartilage matrix degradation. The source of TIMP-1 in the
synovial fluid may be multiple: the cartilage and the syno-
vial membrane. To approach the homeostasis of TIMPs in
joint disease one can measure their levels in synovial
fluid25,38,39. In synovial fluid the level of TIMP-1 is highly
correlated with the levels of MMP-1 and MMP-3, meaning
that it indirectly reflects the level of MMPs25. Therefore,
variations in TIMP-1 levels might reflect periods of cartilage
matrix degradation. Indeed, in patients with knee injury
there is an increase in biological markers in the synovial
fluid, including an increase in TIMP-140. There was no
difference in synovial fluid level of TIMP-1 when comparing
knee OA at different stages of disease progression25. This
suggests that production of TIMP-1 is still effective even at
a late stage of the disease. Although synovial fluid level of
TIMP could be very informative41, its use is not feasible in
current practice of hip OA.
We evaluated hyaluronic acid as a marker of synovial
membrane inflammation and found no prognostic value in
hip OA. Previous results suggested that HA was not corre-
lated with the stage of knee OA42. However, in a 5-year
prospective study in knee OA, it was shown that HA serum
level at entry (as well as increase in the cartilage oligomeric
matrix protein (COMP) serum level during the first year) is
helpful in identifying patients with more rapid disease
progression35,43. In our study in hip OA, increased HA was
related only to the bilateral form of the disease. The finding
of higher serum HA levels in patients with bilateral hip
OA supports the notion that circulating HA reflects more
the diffusion of the OA process than it does cartilage
metabolism of a single joint.
Only a few studies have been interested in the prog-
nostic value of biological markers in patients with hip OA.
The COMP serum level, but not bone sialin protein (a
marker of bone turnover), was also associated with pro-
gression of hip OA in a 1-year prospective study44. Serum
C reactive protein, measured by a highly sensitive neph-
elemetry method, is increased in rapidly destructive hip
OA45. It also appears to be an interesting marker of disease
progression in knee OA46.
In conclusion, this study suggests that serum level of
TIMP-1 may be added to the list of risk factors involved inhip OA progression such as age, sex, BMI, pattern of
femoral head migration, lack of osteophytes and advanced
JSN15,16. A cut-off value of 600 ng/ml of TIMP-1 appears to
be of prognostic value in detecting patients with rapid
disease progression. TIMP-1 might be a surrogate marker
of OA progression that could be of particular interest for
detection of patients at risk of progressive hip OA.References
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